Biotech
Syncell
Syncell raises $15M Series A at $75M valuation
$15M
Total Raised
Series A
Latest Round
2020
Founded
60+
Employees
Taipei, Taiwan
1 min read
Quick Facts
Valuation
$75M
Latest Round Size
$15M
Latest Round Date
December 2024
Syncell: Series A Funding Round
Syncell has successfully raised $15M in Series A funding, reaching a valuation of $75M.
Company Overview
Cell therapy manufacturing platform for regenerative medicine
Funding Details
The Series A round was led by Taiwania Capital, with participation from KdT Ventures.
Company Information
- Headquarters: Taipei, Taiwan
- Founded: 2020
- Employees: 60+
- Category: Biotech
Investment
Syncell plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Taiwania Capital: Verified investor in Series A
- KdT Ventures: Verified investor in Series A
Key Investors
Taiwania Capital
Lead Investor
Verified investor in Series A
KdT Ventures
Investor
Verified investor in Series A
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min read•$250M